EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Innovent Biologics's enterprise value is HK$60,113 Mil.
Innovent Biologics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,788 Mil. Therefore, Innovent Biologics's EV-to-Revenue for today is 8.86.
The historical rank and industry rank for Innovent Biologics's EV-to-Revenue or its related term are showing as below:
HKSE:01801'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.66 Med: 20.88 Max: 1108.69
Current: 8.86
During the past 8 years, the highest EV-to-Revenue of Innovent Biologics was 1108.69. The lowest was 3.66. And the median was 20.88.
HKSE:01801's EV-to-Revenue is ranked worse than 52.61% of 1036
companies
in the Biotechnology industry
Industry Median: 7.96
vs HKSE:01801: 8.86
The historical data trend for Innovent Biologics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's EV-to-Revenue
For the Biotechnology subindustry, Innovent Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's EV-to-Revenue falls into.
Innovent Biologics's current Enterprise Value is HK$60,113 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,788 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics's share price for today is HK$39.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$4.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 